Welcome to the JAK Inhibitors Drug Development Summit
Several recent JAK inhibitor drug approvals for rheumatoid arthritis has sparked investment and a reinvigoration of R&D to explore the potential clinical utility of JAK inhibitors to treat patients with oncology, autoimmune and inflammatory diseases.
As such, the inaugural JAK Inhibitors Drug Development Summit arrives as the first industry-dedicated platform for large pharma, innovative biotech and KOLs of academia to harness the full therapeutic opportunity of JAK inhibitors in the clinic.
Focusing on optimized selectivity, drug-drug interactions, safety and efficacy challenges to successfully translate and develop the next generation of superior JAK inhibitors join the leaders in this space as you strengthen your pipelines and leverage expertise to design and create the right clinical strategy.
With numerous clinical candidates demonstrating genuine viability in targeting the JAK/STAT pathway, join the experts in JAK inhibitor development to participate in cross-disciplinary discussions that are transforming JAK Inhibitor strategies into the best and first in class approaches for patients in need.
View the full event guide for further details on speakers, content and how to join those who are re-defining JAK inhibitor drug development.
Earlybird Discounts End This Friday
Meet Our World-Class Speaker Faculty
Chief Executive Officer
Chief Scientific Officer
Chief, Translational Immunology Section
National Institute of Arthritis & Musculoskeletal & Skin Diseases
Associate Professor & Founder/Chief Scientific Officer
Washington University School of Medicine & Nuogen Pharma